Filter by: patients
Home > Community Treatment Reports and Side Effects > Vincristine Treatment Report
What is Vincristine?

Vincristine is an antineoplatic agent used in the treatment of leukemias, Hodgkin's disease, non-Hodgkin's lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. It is used in combination with other agents in regimens for multiple myeloma.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
AIHA (Autoimmune Hemolytic Anemia) 1 0
Ewing's Sarcoma of Bone 1 1 Efficacy_major

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 1
Mild
 0
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with Vincristine

Nausea 1
Hair loss 1
Tiredness 1
Unintentional weight loss 1

Reported Stop Reasons

Why Patients Stopped Taking Vincristine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 2   Course of treatment ended: 100%
Did not seem to work 1   Did not seem to work: 50%
Doctor's advice 1   Doctor's advice: 50%
Side effects too severe 1   Side effects too severe: 50%

See all 2 patients who’ve stopped taking Vincristine

Reported Duration See details about how long patients take this treatment ▼

Stopped Taking Vincristine

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Vincristine

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Vincristine

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of Vincristine

$200+
 0 0%
$100-199
 0 0%
$50-99
 1 100%
$25-49
 0 0%
< $25
 0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 24, 2012.